Things to Know About Vivitrol When Treating Alcoholism

Vivitrol is one of three FDA-approved medications for alcohol use disorder, and the only one administered as a monthly injection. It was originally approved for alcoholism in 2006 — four years before its approval for opioid dependence — and has a well-established evidence base for reducing heavy drinking days and supporting long-term abstinence when combined with counseling. For patients who struggle with taking oral medications consistently, the monthly dosing is often decisive. This guide covers what Vivitrol does for alcohol use disorder specifically, who it works for, what the research shows, and the practical considerations before starting treatment.

How Vivitrol Works for Alcohol Use Disorder

Alcohol affects the brain through multiple mechanisms, but one of the most important is its effect on the endogenous opioid system. When a person drinks, alcohol triggers the release of endorphins — the brain's own opioids — which bind to opioid receptors and produce the rewarding, pleasurable sensation that reinforces drinking behavior. Over time, this reward loop is part of what makes alcohol use disorder so difficult to stop: the brain has learned that alcohol reliably produces a specific chemical reward.

Naltrexone, the active ingredient in Vivitrol, blocks opioid receptors. When someone on Vivitrol drinks alcohol, the endorphin release still happens, but those endorphins cannot bind to their receptors. The chemical reward is blunted or eliminated. Drinking still has its sedative and disinhibiting effects, but the pleasant "buzz" is dampened. Over time, this disrupts the reinforcement loop and reduces both cravings and the impulse to keep drinking once a first drink has been taken.

Importantly, Vivitrol does not make a person sick if they drink. This is a critical difference from disulfiram (Antabuse), which causes severe nausea, flushing, and heart palpitations if any alcohol is consumed. Vivitrol works more subtly — it takes away the reward, not by making drinking aversive, but by making it less pleasurable. Patients who drink on Vivitrol often describe it as "I drank but it didn't do anything for me."

What the Research Shows

The pivotal clinical trial that led to Vivitrol's FDA approval for alcohol dependence was published in JAMA in 2005. The trial followed 624 adults with alcohol dependence over six months, randomized to Vivitrol or placebo injections. The primary finding: patients who received Vivitrol had 25% fewer heavy drinking days compared to placebo. Among patients who were abstinent for at least a week before starting Vivitrol, the medication reduced heavy drinking days by roughly half.

Later analyses and real-world studies have generally confirmed these findings. Vivitrol is particularly effective at reducing the frequency of heavy drinking episodes and supporting patients who have already achieved some period of initial sobriety. It is less effective at producing complete abstinence from the first injection onward — patients who are still actively drinking heavily may reduce their intake on Vivitrol but not stop entirely.

The comparison between Vivitrol and oral naltrexone is also worth noting. Both contain the same active ingredient, but the monthly injection addresses one of the biggest problems with oral naltrexone: adherence. Alcohol use disorder is characterized by impaired impulse control, and remembering to take a daily pill is genuinely difficult for patients in active recovery. A patient who misses their oral dose can drink hours later with full reward; a patient on Vivitrol is covered continuously for the full month.

Who Vivitrol Works Best For

Not every patient with alcohol use disorder is a good candidate for Vivitrol. The medication works best for:

• Patients who have completed initial detoxification — Vivitrol is typically started after at least a few days of abstinence, though unlike the opioid use case, there is no strict requirement to be alcohol-free before the first injection
• Patients who struggle with oral medication adherence — the monthly dosing eliminates the daily decision point
• Patients whose drinking is driven by the rewarding effects of alcohol rather than purely by withdrawal avoidance — these are the patients whose reward systems Vivitrol most directly affects
• Patients with relatively high liver function — naltrexone is metabolized hepatically and can cause further liver stress
• Patients without current opioid use — Vivitrol will precipitate withdrawal in anyone with opioids in their system, the same safety issue that applies to Vivitrol for opioid use disorder
• Patients who have failed previous treatment attempts — research suggests Vivitrol is particularly valuable as a second-line or third-line option after other approaches have not worked

Vivitrol may not be the first choice for patients with severe liver disease, those currently dependent on opioids, pregnant women (where safety data is limited), or patients who strongly prefer daily oral medication or an abstinence-only approach without pharmacotherapy.

Practical Considerations

A few practical things to know before starting Vivitrol for alcohol use disorder:

Cost and insurance. Vivitrol is expensive — the list price is approximately $1,600 per injection, which works out to nearly $20,000 per year. Most insurance plans cover it for alcohol use disorder, but prior authorization is often required. Alkermes, the manufacturer, offers patient assistance programs that can help with out-of-pocket costs for uninsured or underinsured patients. Medicaid covers Vivitrol in all 50 states, though specific requirements vary.

The injection itself. Vivitrol is administered as a 2 mL intramuscular injection into the gluteal muscle. It must be given by a trained healthcare provider — you cannot self-administer. The injection takes a few minutes, and most patients experience some soreness at the injection site for several days afterward. Injection sites are alternated each month.

The combination with counseling. Vivitrol is consistently most effective when combined with counseling — cognitive behavioral therapy, motivational enhancement therapy, or 12-step facilitation. The medication creates the conditions for recovery by reducing cravings and blunting reward; the counseling does the psychological and behavioral work of sustained change. Programs that provide Vivitrol without integrated counseling produce worse outcomes than those that combine both.

Duration of treatment. There is no fixed endpoint for Vivitrol treatment in alcohol use disorder. Most treatment guidelines recommend at least 3-6 months at minimum, with longer durations (1-2 years or more) appropriate for patients who benefit from the medication and whose underlying disease warrants continued treatment. The decision to stop Vivitrol should be made jointly with the prescribing physician and based on clinical stability, not on an arbitrary timeline.

Vivitrol, Naltrexone, and the Sinclair Method

Worth mentioning briefly: the Sinclair Method is an approach to alcohol use disorder that uses oral naltrexone in a specific way — the patient continues drinking, but takes a naltrexone pill 1-2 hours before each drinking episode. Over time, the reward-reinforcement learning that sustains compulsive drinking is supposedly extinguished, and drinking frequency declines naturally.

Vivitrol is not typically used this way because the continuous monthly dosing does not create the same on-off pattern the Sinclair Method requires. Patients interested in the Sinclair Method should discuss oral naltrexone with their physician instead. The approach is evidence-supported but requires high motivation and physician buy-in, and it is not the standard American treatment paradigm. Most US addiction medicine programs use Vivitrol (or oral naltrexone) as part of an abstinence-oriented approach.

How Vivitrol Compares to Other Alcohol Medications

Three medications are currently FDA-approved for alcohol use disorder:

• Naltrexone (oral or Vivitrol injection) — blocks the rewarding effects of drinking. Best for patients whose drinking is reward-driven. Mild-to-moderate side effects.
• Acamprosate (Campral) — mechanism less clearly understood; appears to normalize glutamate signaling disrupted by chronic alcohol use. Taken as three pills daily. Best for patients who have already achieved abstinence and are trying to maintain it. Very mild side effects.
• Disulfiram (Antabuse) — causes severe physical reaction if alcohol is consumed. Taken as a daily pill. Best for highly motivated patients with strong support systems who want an aversive deterrent. Significant safety issues in patients with cardiac or liver disease.

Many addiction medicine physicians consider naltrexone the first-line choice for most patients because of its evidence base, reasonable side effect profile, and the availability of the monthly Vivitrol formulation. Acamprosate is often added or substituted for patients who need additional support. Disulfiram is reserved for specific situations. All three are part of medication-assisted treatment, the evidence-based framework for treating substance use disorders pharmacologically.

Finding Vivitrol Treatment for Alcohol Use Disorder

Vivitrol for alcohol use disorder can be prescribed in addiction treatment programs, primary care practices, and psychiatric offices. Unlike methadone (which requires a federally licensed opioid treatment program) or historically buprenorphine (which required a DEA X-waiver), any physician can prescribe Vivitrol.

Liberation Way's helpline can help you find treatment programs in your area that offer Vivitrol for alcohol use disorder and walk through insurance coverage questions. The helpline is free, confidential, and available 24 hours a day. Call (866) 275-3142 to speak with a treatment specialist.